The first BridgeBio Pharma trade was made in Q1 2020.
Since then Baillie Gifford bought shares nine more times and sold shares on two occasions. The investor sold all their shares in Q4 2022 and doesn't own any shares in BridgeBio Pharma anymore.
Avg closing price
Price range
Sold -500 Thousand shares
Q4 2022
Avg closing price
$9.57
Price range
$6.74
-
$11.52
Increased shares by 3.2% (+15.4 Thousand shares)
Q3 2022
Avg closing price
$10.39
Price range
$7.94
-
$12.36
Sold 10.6% shares (-57.4 Thousand shares)
Q2 2022
Avg closing price
$8.36
Price range
$5.21
-
$12.14
Increased shares by 10.7% (+52.2 Thousand shares)
Q1 2022
Avg closing price
$10.26
Price range
$7.34
-
$17.16
Increased shares by 5.1% (+23.8 Thousand shares)
Q4 2021
Avg closing price
$42.31
Price range
$11.38
-
$53.41
Increased shares by 11.0% (+46 Thousand shares)
Q3 2021
Avg closing price
$53.60
Price range
$46.87
-
$64.24
Increased shares by 34.3% (+107 Thousand shares)
Q2 2021
Avg closing price
$57.11
Price range
$46.47
-
$63.93
Increased shares by 163.8% (+194 Thousand shares)
Q1 2021
Avg closing price
$65.42
Price range
$55.47
-
$72.35
Increased shares by 96.0% (+58.1 Thousand shares)
Q4 2020
Avg closing price
$48.24
Price range
$38.38
-
$71.11
Increased shares by 941.0% (+54.7 Thousand shares)
Q3 2020
Avg closing price
$31.46
Price range
$27.20
-
$42.19
Increased shares by 115.1% (+3.11 Thousand shares)
Q2 2020